These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28605642)

  • 1. Applicability of [
    Snellman A; Rokka J; López-Picón FR; Helin S; Re F; Löyttyniemi E; Pihlaja R; Forloni G; Salmona M; Masserini M; Solin O; Rinne JO; Haaparanta-Solin M
    Neurobiol Aging; 2017 Sep; 57():84-94. PubMed ID: 28605642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
    Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
    Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
    J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
    Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
    Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease.
    Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B
    J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
    Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
    Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
    Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease.
    Higuchi M
    Curr Alzheimer Res; 2009 Apr; 6(2):137-43. PubMed ID: 19355848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.
    Weigand SD; Vemuri P; Wiste HJ; Senjem ML; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Jack CR;
    Alzheimers Dement; 2011 Mar; 7(2):133-41. PubMed ID: 21282074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.
    Rosen RF; Ciliax BJ; Wingo TS; Gearing M; Dooyema J; Lah JJ; Ghiso JA; LeVine H; Walker LC
    Acta Neuropathol; 2010 Feb; 119(2):221-33. PubMed ID: 19690877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative.
    Toledo JB; Toledo E; Weiner MW; Jack CR; Jagust W; Lee VM; Shaw LM; Trojanowski JQ;
    Alzheimers Dement; 2012 Nov; 8(6):483-9. PubMed ID: 23102118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of brain amyloid β deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B.
    Kawai N; Kawanishi M; Kudomi N; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
    Brain Inj; 2013; 27(9):1026-31. PubMed ID: 23662609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
    Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
    J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
    Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
    Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.